相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world data on melanoma brain metastases and survival outcome
Sidsel Pedersen et al.
MELANOMA RESEARCH (2022)
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report
Joanna Placzke et al.
CANCERS (2022)
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
Massimo Aglietta et al.
TARGETED ONCOLOGY (2021)
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
Sarah Knispel et al.
EUROPEAN JOURNAL OF CANCER (2021)
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Victoria G. Atkinson et al.
CANCERS (2021)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2021)
Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
Kristina V. Orlova et al.
CANCERS (2021)
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019
Claus Garbe et al.
EUROPEAN JOURNAL OF CANCER (2020)
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson et al.
MELANOMA RESEARCH (2020)
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra Van Wilpe et al.
ONCOIMMUNOLOGY (2020)
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Gender Differences and Outcomes in Melanoma Patients
Francesca Morgese et al.
ONCOLOGY AND THERAPY (2020)
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
Fausto Petrelli et al.
MELANOMA RESEARCH (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
Elham Vosoughi et al.
BMC CANCER (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Sara Di Lorenzo et al.
CANCER BIOLOGY & THERAPY (2016)
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review
Francesco Spagnolo et al.
CANCER TREATMENT REVIEWS (2016)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V. Long et al.
LANCET ONCOLOGY (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001-2008 Hospitalization Records
Prisco Piscitelli et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
International trends in the incidence of malignant melanoma 1953-2008uare recent generations at higher or lower risk?
Friederike Erdmann et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Melanoma incidence and mortality in Europe: new estimates, persistent disparities
A. M. Forsea et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
Number of Metastases, Serum Lactate Dehydrogenase Level, and Type of Treatment Are Prognostic Factors in Patients With Brain Metastases of Malignant Melanoma
Thomas K. Eigentler et al.
CANCER (2011)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
